Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 Once vs Twice Daily in COPD
NCT02371629Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 4 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02371629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371629.